Dupilumab as a targeted therapeutic strategy for Th2-driven cutaneous manifestations in Kimura disease
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Dear Editor,
Kimura disease (KD) is a rare, chronic inflammatory condition characterized by subcutaneous nodules, lymphadenopathy, peripheral and tissue eosinophilia, and markedly elevated serum IgE concentrations. Although its precise etiopathogenesis remains incompletely defined, accumulating evidence supports its classification as a type 2 immune-mediated disorder, sustained by Th2 lymphocyte activation and overexpression of interleukin (IL)-4 and IL-13 signaling pathways. This immunological milieu promotes eosinophilic infiltration, vascular proliferation, IgE overproduction, and persistent pruritus, ultimately driving both systemic and cutaneous manifestations of the disease. [...]
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
